SEC Form 4 · accession 0001209191-17-031135
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rohit Vishnoi
Director
Period of report
May 8, 2017
Accepted (ET)
May 9, 2017 · 9:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $10.68 | May 8, 2017 | A | 24,000 | A | — | May 7, 2027 | Common Stock | 24,000 | 24,000 | D |
| Restricted Stock UnitsF2,F3 | — | May 8, 2017 | A | 6,000 | A | — | — | Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1The option vests in 36 equal monthly installments and will be fully vested and exercisable on May 8, 2020.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on May 8, 2017. The RSUs vest on the one year anniversary of the date of grant, so long as there has been no break in the Reporting Person's continuous service through such date.